PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007
REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
GHENT, Belgium, Dec. 5, 2013 (GLOBE NEWSWIRE) -- REGULATED INFORMATION
Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article
14 of the Belgian Law of 2 May 2007 regarding the publication of major
shareholdings in issuers whose securities are admitted to trading on a
regulated market (the "Transparency Law"), that it received a notification of
shareholdings from Perceptive Advisors LLC (US).
The above shareholder notified that they have exceeded the 3% threshold and
now hold 2,077,590 long-based Ablynx shares, which represent 4.24% of the
current 48,992,646 outstanding shares of Ablynx.
Full versions of all transparency notifications are available on the website
of Ablynx, under the section Investors.
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 30 programmes in the pipeline and seven Nanobodies at
clinical development stage. Ablynx has on-going research collaborations and
significant partnerships with major pharmaceutical companies including AbbVie,
Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The
Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
pdf format of the press release http://hugin.info/137912/R/1748152/588740.pdf
Press spacebar to pause and continue. Press esc to stop.